Gaginella T S, Maxfield D L
Division of Gastroenterology, Ohio State University, Columbus.
Drug Intell Clin Pharm. 1988 Jul-Aug;22(7-8):623-5. doi: 10.1177/106002808802200724.
Calcium-channel blocking agents can relieve anginal and chest pain associated with hypermotility of the esophagus. Although calcium-channel antagonists differ in their effects on the esophageal body and the lower esophageal sphincter, reduction of lower esophageal sphincter pressure theoretically could result in gastroesophageal reflux and pain. This pain may be difficult to differentiate from chest pain of cardiac origin. An association between calcium-channel blocking agents and chest pain is speculative at this time. However, the possibility of such an effect should be considered by clinicians in the total management of patients. Future clinical studies are warranted to address the issue of the incidence of such an effect and to define more precisely the potential interrelationship among the calcium-channel antagonists, their efficacy in relieving cardiac pain, and their potential liability in inducing chest pain of noncardiac origin.
钙通道阻滞剂可缓解与食管运动亢进相关的心绞痛和胸痛。尽管钙通道拮抗剂对食管体部和食管下括约肌的作用有所不同，但理论上食管下括约肌压力降低可能导致胃食管反流和疼痛。这种疼痛可能难以与心脏源性胸痛相鉴别。目前，钙通道阻滞剂与胸痛之间的关联尚属推测。然而，临床医生在对患者进行全面管理时应考虑到这种效应的可能性。有必要开展未来的临床研究，以探讨这种效应的发生率问题，并更精确地界定钙通道拮抗剂之间的潜在相互关系、它们缓解心脏疼痛的疗效以及它们诱发非心脏源性胸痛的潜在风险。
